A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered NEV801 in Subjects With Advanced Malignancies
Latest Information Update: 19 May 2026
At a glance
- Drugs Camptothecin/podophyllotoxin (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors Neovia Oncology
Most Recent Events
- 13 May 2026 Status changed from recruiting to completed.
- 02 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 02 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.